Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-se...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Jain, Preetesh, Keating, Michael, Wierda, William, Estrov, Zeev, Ferrajoli, Alessandra, Jain, Nitin, George, Binsah, James, Danelle, Kantarjian, Hagop, Burger, Jan, O’Brien, Susan
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2015
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467871/
https://ncbi.nlm.nih.gov/pubmed/25573991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-603670
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky